603207 小方制药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)9.44117.83322.63042.76558.251
总资产报酬率 ROA (%)8.29115.70719.41034.63241.252
投入资产回报率 ROIC (%)9.35817.73722.57142.57356.712

边际利润分析
销售毛利率 (%)60.90065.00065.61465.46359.037
营业利润率 (%)43.83545.97950.53250.05245.165
息税前利润/营业总收入 (%)42.97845.33849.20549.95044.937
净利润/营业总收入 (%)37.43839.50143.25343.15338.342

收益指标分析
经营活动净收益/利润总额(%)99.442100.42399.42597.43396.210
价值变动净收益/利润总额(%)0.0000.0000.0070.9501.442
营业外收支净额/利润总额(%)-0.097-0.121-0.1290.417-0.142

偿债能力分析
流动比率 (X)5.5475.8766.1373.4203.644
速动比率 (X)5.1715.4035.8683.0433.009
资产负债率 (%)12.50011.83711.99418.62019.628
带息债务/全部投入资本 (%)0.8850.8250.2540.1640.490
股东权益/带息债务 (%)11,191.83712,012.42039,219.49360,752.81620,243.307
股东权益/负债合计 (%)700.004744.836733.730437.052409.475
利息保障倍数 (X)-52.765-77.390-39.003-160.364-273.748

营运能力分析
应收账款周转天数 (天)76.92471.80365.70763.80554.195
存货周转天数 (天)106.600111.992104.905118.297106.348